JERUSALEM, Oct. 3, 2011 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN) is pleased to announce that it has received approval from Israel’s Ministry of Health to market and sell the Company’s Deep TMS device to four medical centers for the treatment of major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.
Uzi Sofer, Brainsway’s Chief Executive Officer, commented, “We are very pleased to receive this vote of confidence in the Deep TMS technology from our homeland’s regulatory authority. We are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that we’ve already received in Europe.”
About Brainsway Inc.
Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimulation) systems – novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson’s disease, Alzheimer’s disease, autism and post-traumatic stress disorder.
Our initial focus is the treatment of major depression. The unique technology of Brainsway is based on patents filed by the U.S. National Institute of Health (NIH) and by the company. Brainsway has an exclusive license from the NIH for the patent and technology. Headquartered in Jerusalem, Israel, the company’s ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol ‘BRIN.’
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: Stephen Kilmer
Kilmer Lucas Inc.